PT-141

PT-141 (generic name: Bremelanotide, brand name: Vyleesi®) is a synthetic cyclic heptapeptide and a centrally acting melanocortin receptor agonist. It was developed as a structural analog of Melanotan II but optimized for sexual function effects with reduced tanning activity.

10mg*10vials

$75

Product Information

Target Population & Applications

Approved Indication

Premenopausal women with hypoactive sexual desire disorder (HSDD)

Defined as persistent, distressing low sexual desire not caused by medical, psychiatric, relational, or drug-related factors.

Off-Label / Research Uses

Male erectile dysfunction (ED), especially in patients unresponsive to PDE5 inhibitors
SSRI/SNRI-induced sexual dysfunction (loss of desire, anorgasmia)
Female sexual arousal disorder and orgasmic disorder
Psychological ED and low sexual motivation in both men and women

Contraindicated Groups

Known hypersensitivity to bremelanotide or inactive ingredients
Uncontrolled hypertension or cardiovascular disease
History of priapism (in men)
Severe hepatic or renal impairment
Pregnancy and breastfeeding
Children and adolescents

Mechanism of Action

PT-141 acts as a potent agonist at melanocortin receptors MC4R and MC3R in the central nervous system, particularly in the hypothalamus, amygdala, and limbic reward system.

Core Pathways

Central MC4R activationStimulates the hypothalamic medial preoptic area (mPOA) and paraventricular nucleus (PVN), increasing dopamine release—the primary neurotransmitter driving sexual motivation.
Oxytocinergic modulationEnhances oxytocin signaling to boost sexual arousal, emotional bonding, and sensory responsiveness.
Reward pathway sensitizationIncreases sensitivity in the nucleus accumbens, strengthening sexual reward processing and desire.
Minimal peripheral effectsWeak activity at MC1R results in negligible skin darkening compared to Melanotan II.